Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG vs post-transplant cyclophosphamide for GVHD prevention in allogeneic HSCT for AML
KCT0009953Phase 2Not yet recruiting
- Sponsor
- The Korean Society of Hematology
- Start
- Dec 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of antithymocyte globulin rabbit and cyclophosphamide in acute myeloid leukemia (AML) (2 arms), sponsored by The Korean Society of Hematology. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
antithymocyte globulin rabbitcyclophosphamide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on KCT0009953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009953.